Attitudes to and Understanding of Risk of Acquisition of HIV Over Time: Design and Methods for an Internet-based Prospective Cohort Study Among UK Men Who Have Sex With Men (the AURAH2 Study) by Sewell, J et al.
Protocol
Attitudes to and Understanding of Risk of Acquisition of HIV Over
Time: Design and Methods for an Internet-based Prospective
Cohort Study Among UK Men Who Have Sex With Men (the
AURAH2 Study)
Janey Sewell1, BNurs; Andrew Speakman1, PhD; Andrew N Phillips1, PhD; Valentina Cambiano1, PhD; Fiona C
Lampe1, PhD; Richard Gilson1, MBBS; David Asboe2, MBBS; Nneka Nwokolo2, MBBS; Amanda Clarke3, MBBS;
Ali Ogilvy2, BNurs; Simon Collins4; Alison J Rodger1, MBBS
1Department of Infection and Population Health, UCL, London, United Kingdom
2Chelsea and Westminster Hospital NHS Foundation Trust, London, United Kingdom
3Brighton and Sussex University Hospitals NHS Trust, Brighton, United Kingdom
4HIV i-Base, London, United Kingdom
Corresponding Author:
Janey Sewell, BNurs
Department of Infection and Population Health
UCL
Royal Free Campus
London, NW3 2PF
United Kingdom
Phone: 44 07792096376
Fax: 44 20 3758 2000
Email: j.sewell@ucl.ac.uk
Abstract
Background: The annual number of new human immunodeficiency virus (HIV) infections among men who have sex with men
(MSM) has risen in the United Kingdom and, of those who are HIV positive, the proportion undiagnosed is high.
Objective: The prospective AURAH2 study aims to assess factors associated with HIV acquisition among MSM in the United
Kingdom and to investigate changes over time within individuals in sexual behavior and HIV-testing practices.
Methods: AURAH2 is a prospective study among MSM without diagnosed HIV, aiming to recruit up to 1000 sexually active
MSM attending sexual health clinics in London and Brighton in the United Kingdom. Participants complete an initial paper-based
questionnaire, followed by online follow-up questionnaires every 4 months collecting sociodemographic, health and behavioral
data, including sexual behavior, recreational and other drug use, HIV testing practices, and pre-exposure prophylaxis use, over
a planned 3-year period.
Results: The study is ongoing.
Conclusions: The results from AURAH2 study will provide important insight into established and emerging risk behaviors that
may be associated with acquisition of HIV in MSM in the United Kingdom, changes over time within individuals in sexual
behavior, and information on HIV testing practices. These data will be crucial to inform future HIV prevention strategies.
(JMIR Res Protoc 2016;5(2):e128)   doi:10.2196/resprot.5582
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Introduction
Background
In 2014, the number of men who have sex with men (MSM)
that were newly diagnosed with human immunodeficiency virus
(HIV) continued to rise with 3360 new diagnoses in the United
Kingdom [1]. Currently, there are an estimated 43,500 MSM
living with HIV, of whom around 16% are undiagnosed [2]. It
is thought that MSM unaware of their HIV infection
disproportionately contribute to onward transmission (60-82%
of new transmissions come from people not diagnosed [3,4])
and that delay in diagnosis and treatment is associated with
increased risk to health [5]. HIV prevention approaches have
historically focused on condom use, which, if correctly and
consistently used, is a reliable and established method to reduce
transmission [6]; however, consistent condom use is difficult
to achieve [7,8]. There is a clear need for improved HIV
prevention and testing strategies targeted at HIV negative MSM
to reduce the number of new HIV infections and increase HIV
testing rates.
The AURAH study was a cross-sectional questionnaire study
that collected data from 2013-2014 in a large sample of
HIV-negative patients attending Genito-Urinary Medicine
(GUM) clinics in the United Kingdom with a focus on two
populations: black Africans and MSM [9]. It used a
self-completed questionnaire to assess knowledge of and
attitudes to HIV transmission risks and the role of antiretroviral
therapy (ART), and to assess the prevalence of medical and
psychological symptoms (eg, depression and anxiety), quality
of life, lifestyle factors (eg, drug and alcohol use), and possible
links to sexual risk behaviors. The AURAH2 study will build
on the work of the AURAH study and is the first large
prospective observational study of MSM in the United Kingdom.
It will provide longitudinal data on HIV transmission risk in a
group of HIV negative (at enrollment) MSM using online
questionnaires for data collection over a 3-year period. It will
collect baseline socioeconomic, health and lifestyle information
(including recreational drug use and chemsex) with longitudinal
information on sexual activity, HIV testing, sexual behavior,
and occurrence of new HIV infections among UK MSM.
Understanding attitudes of HIV negative or undiagnosed MSM
towards condomless sex with individuals of unknown HIV
status, and examining risk behavior in the context of
psychological or general health status, history of sexually
transmitted infection (STI), alcohol and drug use, could elucidate
reasons for the observed ongoing HIV transmission among the
UK MSM population. Studies have consistently found
associations between increased sexual risk behavior, such as
condomless anal sex and group sex [10-13], with recreational
drug use, and longitudinal data has highlighted the bi-directional
relationship between sexual pleasure and drug use [14].
Longitudinal data from Australia has demonstrated an
association between drug use and increased risk of HIV
infection, in particular the use of oral erectile dysfunction
medication in combination with methamphetamines to enhance
sexual pleasure [12], and similar evidence was recently reported
from a US study that showed a clear link between increased
sexual risk behavior and starting methamphetamine use [15].
Although not a new concept in the United States [16-18], a
recent UK report on “chemsex” [19], which is defined as the
use of certain sexually disinhibiting recreational drugs for
facilitating or enhancing sex, has highlighted a need for more
research into behaviors that put MSM at high risk of HIV and
STI acquisition as a public health priority. Longitudinal data
on recreational drug use, chemsex and associations with high
risk sexual behaviors, such as group sex, in HIV negative or
undiagnosed MSM would provide valuable insight into potential
causes for the observed increases in HIV and STI acquisition
among MSM in the United Kingdom.
Reducing the large proportion of MSM with undiagnosed HIV
that potentially contribute to onward transmission of HIV is a
public health priority [20], and data from HIV-negative or
undiagnosed MSM in the United Kingdom are currently needed
to inform and develop better provision of HIV testing options.
Despite high coverage (86%) of HIV testing among MSM
attending sexual health clinics [21], generally the frequency of
HIV testing among UK MSM remains low (estimated 30%
never tested, 75% not in past year) [4], and alternative ways to
test for HIV, other than through sexual health clinics, are
urgently required [1]. HIV self-testing (HIVST) was made legal
in the United Kingdom in April 2015 [22] and is defined by the
test being collected, performed, and interpreted in private by
the individual who wants to know their HIV status [23]. HIVST
has the potential to alleviate some of the perceived barriers to
other forms of HIV testing, such as stigma, discrimination, and
inaccessibility of health services [24], due to the environment
the test is performed in, which may encourage more people to
test. Increased HIV testing and resulting diagnoses could have
prevention benefits if newly diagnosed men are more likely to
use condoms and have fewer sexual partners after diagnosis
[25,26]. However, it is not known whether the availability of
HIVST will increase the diagnosis rates of HIV in the United
Kingdom. The AURAH2 study will seek to collect information
on the acceptability and uptake of HIVST as it becomes more
widely available.
The expansion of HIV testing options is also of particular
relevance since it was demonstrated that HIV transmission is
preventable through ART in 2011 [27]. Evidence that ART
greatly reduces onward sexual transmission of HIV in MSM
[28], as well as heterosexuals [27,29], was demonstrated through
the interim results of the PARTNER study [28]. Furthermore,
the concept of treatment as prevention (TasP) has been widely
explored as an HIV prevention strategy and is recommended in
the British HIV Association’s treatment guidelines to prevent
onward transmission [30]. However, access to and uptake of
ART is dependent on a person knowing their HIV status and,
in the United Kingdom, research has shown that although
widespread ART coverage among MSM at a population level
may reduce HIV infectivity, it is unlikely to reduce the number
of HIV transmissions in the absence of increased coverage and
frequency of HIV testing [31]. There is some evidence that
sexual risk behavior declines after an HIV diagnosis, as it has
been demonstrated that behavior is modified to prevent onward
transmission [25,26]. However, this has not been explored in
the context of TasP, and little is known regarding changes in
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sexual behavior during primary HIV infection (a period
characterized by very high infectiousness) and on the variability
in sexual risk behavior over time at an individual level (eg, the
duration of periods of very high risk). There are cohort studies
of MSM that provide some information on these issues from
Europe, the United States, and Australia [32-35]; however, there
have been no follow-up studies among individuals at risk of
HIV infection in the United Kingdom, which the AURAH2
study will seek to address. The role of TasP is also critical in
HIV-negative MSM’s sexual decision making and risk reduction
behaviors and, as yet, is largely unexplored among UK
HIV-negative MSM. Further investigation is needed, particularly
in light of TasP, into the risk reduction strategies that HIV
negative or undiagnosed MSM utilize at a community level
[36], such as sero-sorting (choosing a partner of believed
sero-concordant status), negotiated safety (condomless sex with
a sero-concordant main partner), strategic positioning (choosing
a different sexual position or practice depending on the
sero-status of a partner), and withdrawal (in which the negative
partner is receptive during intercourse but without ejaculation
by his partner) [37]. To investigate the role of TasP in sexual
decision making and risk reduction strategies, the AURAH2
study will collect data to inform on these themes, including
information on knowledge of an HIV-positive partner’s viral
load. Collection of longitudinal data will help describe the sexual
behaviors and risk reduction strategies among HIV negative
MSM and assess the extent to which patterns of sexual behavior
and condomless sex change over time within individuals. This
information will play a key role when developing effective,
targeted HIV prevention strategies.
A further significant development for HIV prevention strategies
that the AURAH2 study will provide information on is
pre-exposure prophylaxis (PrEP), which has been used as an
HIV prevention tool for HIV-negative men in the United States
since 2012 [38]. Although PrEP is not currently available on
the UK National Health Service (NHS), generic formulations
have been increasingly available via websites. In 2015, the
results from the UK PROUD study [39] and the French
IPERGAY study [40] demonstrated that daily [39] and “on
demand” [40] dosing of Truvada, the antiretroviral tablet used
for PrEP, reduced the risk of HIV acquisition in HIV-negative
men by 86%. There has been increasing community [41] and
clinical [42] pressure to make PrEP available through the NHS.
New PrEP websites that have been developed by activists
[43,44] acknowledge the potential to access PrEP in a number
of different ways that include ordering it online, which may
challenge how the access and uptake of PrEP is monitored and
may lead people to obtain PrEP without the appropriate
counselling and follow-up [42]. Self-reported changes in
attitudes, access to, and use of PrEP and factors associated with
PrEP use by HIV negative men in the United Kingdom will be
vital to inform policy and inform on acceptability and uptake
of PrEP in sexually active HIV-negative gay men.
The landscape of HIV prevention is changing as concepts such
as TasP and PrEP are introduced, and advances in HIV testing
technologies potentially make testing for HIV more accessible.
In conjunction with evolving HIV prevention strategies,
emerging patterns in lifestyle choices that affect sexual behavior
are important to consider if current and effective HIV prevention
interventions are to be designed and implemented. The
information provided by the AURAH2 study will contribute to
the understanding of the social, psychological, and health-related
factors that are linked to high-risk sexual behaviors that
potentiate transmission of HIV. The study will provide data
highly relevant to HIV prevention efforts among MSM and will
help inform national policies aimed at reducing HIV incidence
and increasing HIV testing in the United Kingdom.
Study Aims and Objectives
The aim of the AURAH2 study is to evaluate the incidence and
predictors of new infections among HIV-negative MSM at risk
of acquiring HIV and to assess changes over time in risk
behavior and testing practices within individuals.
The detailed study objectives are to assess:
1. In MSM without diagnosed HIV:
(i) the prevalence and correlates of specific sexual behaviors,
including numbers of condomless sex partners, condomless sex
with casual partners and partners of unknown HIV status,
insertive/receptive condomless sex, and other specific
higher-risk sexual activities such as group sex and chemsex
(ii) the number of condomless sex partners before, during, and
after the estimated period of primary HIV-infection and time
of HIV diagnosis in men who become infected during the study,
as well as correlates of within-person changes in sexual behavior
(iii) the frequency and type of HIV testing accessed over time
(sexual health clinic, self-testing, general practitioner, surgery,
hospital, other)
2. The extent to which baseline demographic, socioeconomic,
and health and lifestyle factors (including recreational drug use
and chemsex) are predictive of subsequent levels of condomless
sex, incident HIV infection, and HIV-testing behaviors
3. The association of attitudes to HIV transmission, disclosure,
treatment, and prognosis, with high-risk sexual behaviors,
HIV-testing behaviors, and subsequent HIV acquisition
4. The associations of participant characteristics, sexual
behavior, and attitudes with reported use of, and willingness to
consider use of, post exposure prophylaxis (PEP) and PrEP
Methods and Design
Study Design
AURAH2 is a prospective cohort study of UK MSM not
diagnosed with HIV. Baseline information is collected on each
participant through the AURAH study paper questionnaire [9],
which is completed during a sexual health clinic attendance.
Follow-up questionnaires are made available online every 4
months through the study website and consist of two brief and
one extensive questionnaire per year. Online follow-up will
continue for up to 3 years from the time a participant joined the
study during the recruitment period in 2015.
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Population and Setting
HIV negative or undiagnosed MSM adults attending sexual
health clinics at three sites in the United Kingdom for STI
screening or HIV testing are eligible to take part in the study.
The three clinical sites are as follows: The Mortimer Market
Centre, London; 56 Dean Street Clinic, London; and the Claude
Nicol Centre, Brighton.
These three clinical sites were chosen based on their ability to
provide access to large numbers of MSM attending sexual health
services and previous successful collaboration with the
researchers for the AURAH study [9]. During the AURAH
study recruitment process, the three sites demonstrated their
ability to provide a broad sample of homosexually active men,
including gay, bisexual, and non-gay identified MSM.
The eligibility criteria to join the study is (1) self-reported
HIV-negative, (2) self-defining as MSM, (3) being aged 18
years or over, (4) attending or having previously attended for
routine STI or HIV testing in the study clinics, and (5) willing
to be contacted for longitudinal follow-up for up to a 3-year
period.
Sample Size
The sample size calculation was based on our objective to assess
within-person changes in sexual behavior after receiving an
HIV diagnosis. This outcome is more constrained by power
than others because it relies on comparisons of participants
within the group who are infected with HIV during follow-up.
For sexual behavior classified as whether or not a man reports
>3 condomless sex partners in the past 3 months, 85 new HIV
diagnoses would be needed to detect, with 80% power and 5%
significance level, the following changes: 17 (20%) men newly
diagnosed switching from >3 to ≤3 condomless sex partners
pre to post diagnosis, and 4 (5%) men newly diagnosed
switching from ≤3 to >3 condomless sex partners pre to post
diagnosis. With 1000 HIV-negative men initially enrolled in
the study sample, assuming an annual HIV incidence of 4% (for
high-risk MSM) and a dropout rate of 15% per year, 96 new
HIV infections would be expected to accrue over a 3-year
period. This sample size of 1000 should provide adequate power
for the other objectives.
Recruitment
Participants are recruited to the AURAH2 study through two
separate recruitment routes. The recruitment route 1 group
consists of HIV negative or undiagnosed MSM who were (1)
enrolled in the AURAH cross-sectional study [9] from the three
clinics detailed above during targeted recruitment of MSM (until
March 2015) and (2) who had indicated interest in future
follow-up on the AURAH study consent form. An email
invitation to participate in the AURAH2 study was sent to this
group from the AURAH2 study website in March 2015.
Participants who joined the AURAH2 study from AURAH were
assigned the same study number in their online follow-up as
their original AURAH study number so that online follow-up
could be linked to responses in the original cross-sectional study.
The recruitment route 2 group consists of HIV-negative or
undiagnosed MSM who are prospectively recruited in person
through the three clinic sites from March 2015 until December
2016. This group is directly consented into the AURAH2 study
in their sexual health clinic and completes the baseline AURAH
paper questionnaire during their clinic attendance. Online
registration with the study website using a personal smartphone
or iPad is explained during the consent procedure, or participants
are contacted within 2 weeks with an email invitation to register.
Consent
Consent for the study is gained through two mechanisms,
according to the recruitment route. Participants from recruitment
route 1 (contacted in March 2015) were required to complete
an online consent form for the AURAH2 study. This was
presented to them on the study website after they had read the
online patient information sheet and prior to registration.
Consent for participants via recruitment route 2 is obtained at
study enrollment in the clinic setting via a paper-based
information sheet and consent form. Participants recruited
through recruitment route 2 do not need to complete an
additional online consent form as information on the AURAH2
study is provided in the Patient Information Sheet. In both
consent processes, participants are (1) made aware of the study
aims, (2) made aware that participation means they are expected
to complete brief online questionnaires about sexual behavior
and HIV testing on a regular basis over a 3-year period, (3)
asked to provide their email address and mobile phone number
and consent to receive reminders to complete the online
questionnaires via email and/or text message, but are also told
that there will be a maximum of two reminders by email
followed by one text message if they do not respond, (4) asked
to provide their full name and date of birth and made aware that
this information will be used to link with matching data in UK
national clinical databases including the national HIV/AIDS
Reporting System (HARS) database (see clinical data), (5) made
aware that results of any HIV test results from the day they
joined the study, or that they self-report during the study period
(up to 3 years), will be recorded and stored securely and
separately from the study questionnaire, (6) made aware that
they can withdraw from the study at any point and ask for their
personal data to be deleted and that this will not affect their care
at their GUM clinic, and (7) advised that should they wish to
withdraw from the study they should send an email to a specified
contact address to make this request.
Online Registration Procedure
Participants are sent a maximum of three “invitation to register”
messages via the study website (see below). The first contact
is an email containing an individualized link, which, when
selected, allows the recipient to register an account with the
study website. A second similar reminder email is sent a week
later to participants who have not registered, and finally a text
message is sent a week after the second email (if a mobile phone
number was provided during the consent procedure). In each
email, participants are provided with information on how to opt
out of the study and any further contact. Participants who do
not register within 1 week after the two reminder emails and a
text message have been sent are removed from the study lists
and not contacted further.
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Website Design and Features
The AURAH2 website was designed to provide full information
on the study to the general public and the study participants.
The home page provides a login box that allows only registered
participants to gain access to the study questionnaires by
entering a username and password. Once a participant has
registered and completed the first online questionnaire,
automated reminder emails are sent every 4 months when
follow-up questionnaires are due. Each reminder email informs
the participant that a questionnaire is due for completion and
contains a link to the study website homepage to login and
access a questionnaire. The message also contains information
on how to receive a username and password change prompt if
login details have been forgotten. If a participant does not log
in and complete a questionnaire, a second automated reminder
email is sent 1 week after the initial email, and a final reminder
is sent by text message a week later. If a participant does not
log in and complete a questionnaire after the third reminder, no
further contact is made until the next questionnaire is due, 4
months later.
The secure website provides facilities for content management
including the ability to change information pages and add new
items and details of study publications. The administration pages
are accessible only to user accounts controlled by the study
coordinator and data manager. From the administration pages
of the website, the “invitation to register” and follow-up
messages are managed and the status reports and questionnaire
results data can be securely downloaded on a regular basis.
Study Questionnaires
Baseline Data
Extensive baseline data are collected through the pen-and-paper
AURAH baseline questionnaire, details of which have been
published elsewhere [9]. The questionnaire gathers detailed
information on demographics, socioeconomic factors, physical
and psychological health and well-being, knowledge and
understanding of HIV and antiretroviral treatment, lifestyle
factors (smoking, alcohol, and recreational drug use), HIV
testing, knowledge and use of PEP, and sexual behavior. Both
recruitment routes use the baseline AURAH questionnaire for
initial data collection, which takes approximately 20-25 minutes
to complete.
Online Questionnaires
Online data collection every 4 months will be ongoing until
2018. It consists of a brief online questionnaire that assesses
sexual risk behavior, HIV testing history, self-reported STIs,
and use and frequency of chemsex drugs from the preceding 3
months. The basic 4-monthly online questionnaire takes
approximately 5 minutes to complete. A more detailed
questionnaire is undertaken on an annual basis that includes the
information collected in the 4-month questionnaire and
additional information on use of HIV testing preferences, PEP
and PrEP, physical and psychological symptoms, and attitudes
to HIV transmission. The annual online questionnaire takes
approximately 20 minutes to complete.
Each online questionnaire commences with a question on the
most recent date and result of a participant’s previous HIV test.
If a participant consistently reports negative HIV test results or
“not tested,” then the questionnaires remain specific to an HIV
negative or unknown status. However, if a participant reports
a positive HIV test result, the questionnaire is programmed to
collect information on the number of partners, sexual behavior,
and recreational drug use pre and post diagnosis. At each
subsequent login, an HIV-positive participant will complete
questionnaires that are similar to the HIV-negative participants,
but tailored to reflect the HIV-positive sero-status of the
participant. A flowchart to demonstrate recruitment from clinic
to the online questionnaire sequence is shown in Figure 1.
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Figure 1. Flowchart of AURAH2 recruitment and questionnaire sequence.
Clinical Data
The result of any HIV test taken in clinic at the same time as
the baseline questionnaire completion is stored as part of the
study records. At each online follow-up questionnaire,
participants are asked to self-report the result of their most recent
HIV test and any diagnosed STIs. At the end of the study period,
in collaboration with Public Health England, data will be
checked against corresponding records and data in national
clinical databases such as HARS, the Genitourinary medicine
clinical activity dataset (GUMCAD), and the Office for National
Statistics. The linkage of the AURAH2 data to these databases
will provide confirmation on the self-reported HIV status of
participants as well as identify any new HIV diagnoses that
have not been self-reported through the questionnaires.
Data Processing and Security
Baseline paper questionnaires completed in clinic are collected
by the study nurses and transferred regularly to the study
management center via registered post or collected in person
from the clinic sites by the study researchers. At the study
management center, the original paper questionnaires are stored
securely in locked cabinets. Baseline questionnaires are
identifiable only by an assigned study number to maintain
confidentiality, and participant details linked with the study
number are collected in a separate study log. The study log is
maintained securely and updated daily at each clinical site. The
study log contains study numbers, clinic identifiers, and details
of consent status for all patients invited to participate in the
study, whether or not HIV and other STI tests had been done,
and the result of any HIV test. Contact details of participants
are also entered in the log. A copy of the study log (with contact
details removed for non-consenting participants) is transferred
on a regular basis to the study management center using the
NHS mail system, which is approved by the Department of
Health for the purpose of sharing personal identifiable
information and sensitive information.
Baseline questionnaires are digitized at the management center
using the REDCap data capture system for secure double data
entry. The study website is hosted in a secure data center and
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network environment, and the online questionnaire response
datasets are directly downloaded to encrypted data drives at the
study management center on a monthly basis. Linkage to Public
Health England’s datasets will be done at the end of the study
using limited participant identifiers: surname Soundex, sex, and
date of birth.
The final resulting study datasets, including scanned images of
the questionnaires, are stored on the University College London
Data Safe Haven, which is a secure technical solution for storing,
handling, and analyzing identifiable data. This has been certified
to the ISO27001 information security standard and conforms
to the NHS Information Governance Toolkit.
The contact details of any participants who did not join the
AURAH2 study after the email invitations from recruitment
route 1 were removed from the study records 1 month after their
final email reminder or the text message had been sent (if
provided). All AURAH2 participants contact details will be
erased from the study database 6 months after the completion
of the study.
Ethics Approval
The research protocol and all versions of the study documents
(information sheet, consent form, questionnaires, and versions
of the online questionnaires) were approved by the designated
research ethics committee (NRES committee
London-Hampstead, ref: 14/LO/1881 in November 2014). Based
on these documents, the study subsequently received permission
for clinical research at the three participating National Health
Service sites: Chelsea and Westminster NHS Foundation Trust,
Central and North West London NHS Foundation Trust, and
the Brighton and Sussex University Hospitals NHS Trust.
Results
Data collection commenced in March 2015 and is ongoing until
March 2018. Initial results from analysis of the baseline
questionnaires are expected in 2016, and results from
longitudinal data are expected in 2018.
Discussion
Principal Considerations
The AURAH2 study will provide important longitudinal data
on sexual risk behavior, HIV testing habits, and risk factors for
ongoing transmission of HIV in UK MSM who were HIV
negative at entry to the study but who are at risk of HIV
infection. It uses a novel approach to data collection by
combining paper-based questionnaires collected in the clinic
setting and online follow-up questionnaires that participants
access at their convenience. We applied a short recall period of
3 months in the questionnaire responses to maximize self-report
accuracy and diminish recall bias [45] and to better capture
within-person changes over time in sexual behavior. The request
to complete questionnaires was sent on a 4-monthly basis to
decrease the study burden for the participant and reduce attrition
during the long follow-up period. The online recall period is
reflective of the timeframes that are used in the paper-based
questionnaires and is closely aligned to the frequency of survey
completion in an attempt to capture ongoing and new behavioral
information. The Internet has been increasingly used as a tool
with which to collect survey data as it offers a low-cost, flexible,
and fast way to collect data while reducing participant burden
[46], and Internet surveys have been shown to be an acceptable
method in researching MSM at risk of acquisition of HIV [47].
A similar study to AURAH2 is currently being conducted in
the United States, using online follow-up over a 3-year period
in a sample of 1000 gay and bisexual men who will complete
self-administered HIV/STI tests and online surveys [48], which
may offer comparisons of survey response rates and attrition
over the 3 years. Despite some design differences, notably in
recruitment routes (ie, the One Thousand Strong study recruited
in partnership with a marketing firm via email invitation as
opposed to face to face in sexual health clinics) and methods
(ie, AURAH2 does not use biological methodologies for
HIV/STI tests [48]), both studies will demonstrate the feasibility
of using the Internet to engage MSM in online data collection
and contribute substantial insight into sexual risk behavior and
HIV testing. Longitudinal online follow-up in the HIV negative
or undiagnosed population has not been widely explored among
MSM in the United Kingdom but will be key to understanding
how individual sexual behaviors change over time. The annual
Gay Men’s Sex survey “Vital Statistics” has been successfully
conducted among participants since 1993, although the survey
is a one-off online survey [49], as opposed to the follow-up and
retention of the same group of individuals over time. The
AURAH2 study will provide valuable insight into the feasibility
of recruiting and retaining MSM in a study that requires regular
ongoing follow-up over a period of 3 years using the Internet
as a tool for data collection.
Limitations
A recognized limitation of the study is the restricted recruitment
of MSM from attendance at GUM clinics, which may not be
reflective of the wider MSM population, and in particular from
the two clinics (56 Dean Street and the Mortimer Market Clinic)
that provide services for patients seeking support for drug use.
However, recruitment is from the general clinic attendees, not
from specific drug use services. Although the majority of MSM
in London do appear to be engaged with GUM sexual health
services [50], there is less information on engagement with these
services in the rest of the United Kingdom, so recruiting from
a site outside London will allow some comparison. Recruitment
through GUM clinics was essential for this study so that the
self-reported HIV test results of participants could be confirmed
with UK national clinical HIV databases (in collaboration with
Public Health England) and so that the study sampling frame
was clearly based on MSM who had attended a sexual health
clinic. Recruitment online or through other settings could have
potentially provided larger numbers of anonymous participants
but would have been limited by the inability to confirm HIV
status during or at the end of the study period due to participant
anonymity.
We identify a further limitation of the study in the lack of
recruitment from clinical sites outside two major cities that have
large gay communities. It is recognized that this will limit the
study’s generalizability given the potential differences in
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lifestyle, HIV testing opportunities, and access to sexual health
services between urban and rural settings. Future studies might
address this issue using the Internet or other digital platforms
to enroll participants so that a broader sample of MSM from
across the United Kingdom could be included.
Conclusion
Evidence that HIV incidence is increasing among MSM in the
United Kingdom [1] indicates a clear need for ongoing research
in this group. The AURAH2 study will provide detailed
longitudinal data on the incidence and predictors of new
infections among HIV-negative MSM at particular risk of HIV
infection and will further provide some of the first data on
emerging behaviors such as chemsex that have raised concern
for sexual health and well-being among MSM, as well as interest
and uptake of PrEP and expanded HIV testing options for this
group. The study completed recruitment of participants in March
2016, and it is hoped that the wide range of topics explored by
the AURAH2 study renders results that will help improve a
variety of targeted health promotion strategies that are specific
to the men that need them. The study will be highly relevant to
HIV prevention efforts among MSM, and it is planned for the
data to feed into a mathematical model that simulates different
scenarios to inform prevention strategies [4,51,52]. The results
of the study will also inform national policies aimed at reducing
HIV incidence and increase HIV testing in the United Kingdom
in this population.
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